Core Viewpoint - Dongcheng Pharmaceutical (002675.SZ) successfully passed the FDA's cGMP inspection for heparin sodium raw materials, enhancing its competitiveness in the international market and supporting its expansion into the global market [1] Group 1 - The company underwent an FDA cGMP inspection from December 8 to December 11, 2025 [1] - The company received the Establishment Inspection Report (EIR) from the FDA, confirming compliance with cGMP requirements [1] - The successful inspection indicates the company's quality system continues to meet FDA standards, providing a solid foundation for expanding its heparin sodium raw materials in the U.S. market [1]

Group 1 - The company, Guoyao Modern, produces various products including paracetamol tablets, acetaminophen and codeine tablets, lofecam and codeine tablets, and diclofenac sodium sustained-release tablets, which are used for antipyretic and analgesic purposes [2]

Core Viewpoint - The company expects a net profit of 40 million to 50 million yuan for the year 2025, marking a turnaround from losses to profitability [1] Group 1: Financial Performance - The company anticipates a significant improvement in net profit attributable to shareholders, achieving a turnaround from losses [1] - The expected net profit for 2025 represents a substantial increase compared to previous years [1] Group 2: Business Drivers - The primary drivers for this turnaround include a substantial increase in the scale of GLP-1 formulations and raw material business [1] - The advancement of the CRDMO (Contract Research, Development, and Manufacturing Organization) business is also contributing to the company's growth [1] Group 3: R&D Investment - The company is increasing its investment in research and development, particularly in innovative drugs like HY3003, to enhance the competitiveness of its core products [1]

Core Viewpoint - Jinshi Yao (300434.SZ) expects a net profit attributable to shareholders of 118.91 million to 154.45 million yuan for 2025, representing a year-on-year growth of 29.58% to 68.31% [1] Group 1: Financial Performance - The company anticipates a net profit of 97.90 million to 133.44 million yuan after deducting non-recurring gains and losses, indicating a year-on-year growth of 18.96% to 62.15% [1] - The overall business remains stable, with profit growth supported by effective budget optimization and cost control measures [1] Group 2: Business Development - The new materials and machinery sectors have benefited from successful commercialization of prior R&D results, leading to improved sales gross margin and gross profit [1] - Increased demand for cold medicine has positively impacted sales of anti-influenza virus products, further enhancing the company's profitability [1] Group 3: Non-recurring Gains - The estimated impact of non-recurring gains and losses on net profit is approximately 21.01 million yuan [1]

Group 1 - The company expects a net profit attributable to shareholders for the year 2025 to be between -375 million and -315 million yuan [1] - The net profit after deducting non-recurring gains and losses is also projected to be between -375 million and -315 million yuan [1] - The main reasons for the performance change include a decrease in sales prices, operating costs and period expenses remaining at the same level as the previous year, and the provision for significant credit impairment losses and non-recurring gains and losses [1]

（记者 王瀚黎） 每经头条（nbdtoutiao）——从极寒测试到万套装车！半固态电池今年有望搭载多款新车：各大厂商摩 拳擦掌，动力电池技术迎来迭代年 每经AI快讯，哈三联1月28日晚间发布公告称，公司第五届第二次董事会会议于2026年1月28日以通讯 表决的方式召开。会议审议了《关于2026年度日常关联交易预计的议案》等文件。 ...

Core Viewpoint - The company successfully passed the FDA cGMP inspection for heparin sodium raw materials, indicating compliance with FDA standards and enhancing its competitiveness in the international market [1] Group 1: FDA Inspection Results - The company underwent an FDA cGMP site inspection from December 8 to December 11, 2025 [1] - The inspection result was classified as NAI (No Action Indicated), meaning no further action is required [1] Group 2: Market Implications - The successful FDA inspection strengthens the company's quality system in line with FDA cGMP requirements [1] - This achievement provides a solid foundation for the company to expand its heparin sodium raw materials in the U.S. market [1] - The positive outcome is expected to have a beneficial impact on the company's global market expansion efforts [1]

Group 1 - The chemical pharmaceutical sector experienced a decline of 0.72% on January 28, with Bibete leading the drop [1] - The Shanghai Composite Index closed at 4151.24, up 0.27%, while the Shenzhen Component Index closed at 14342.9, up 0.09% [1] - Notable gainers in the chemical pharmaceutical sector included Guangshengtang, which rose by 14.00% to a closing price of 105.01, and Xinnowei, which increased by 12.90% to 46.21 [1] Group 2 - Bibete saw a significant decline of 13.61%, closing at 46.26, with a trading volume of 103,400 shares and a transaction value of 4.92 million [2] - The sector experienced a net outflow of 1.74 billion in main funds, while retail investors saw a net inflow of 1.274 billion [2] - The top stocks by main fund inflow included Guangshengtang with 1.65 billion and Xinnowei with 79.25 million [3]

Core Viewpoint - Chengda Pharmaceutical is forecasting a net loss attributable to shareholders of the listed company for the year 2025, estimated between 11 million to 18 million yuan, with a net loss excluding non-recurring gains and losses projected between 27.5 million to 34.5 million yuan [1] Group 1: Financial Performance - The company has implemented effective sales strategies and market development efforts, leading to a steady increase in operating revenue [1] - The expansion of fixed assets due to completed fundraising projects has resulted in increased depreciation and amortization expenses [1] - The wholly-owned subsidiary, Shanghai Jiuqian Cheng Biomedical Co., Ltd., is still in the research and development phase for innovative drugs and has not yet generated revenue [1] Group 2: Impairment and Non-Recurring Gains - The company conducted impairment tests on inventory and investment properties at the end of the reporting period, leading to the recognition of impairment provisions, which negatively impacted net profit [1] - Non-recurring gains and losses are expected to affect net profit by approximately 16.5 million yuan, primarily from government subsidies and cash management investment income [1] Group 3: Year-on-Year Comparison - Despite the forecasted losses, the company expects a reduction in the loss margin compared to the same period last year [1]

智通财经APP讯，哈三联(002900.SZ)披露2025年度业绩预告，公司预计归属于上市公司股东的净亏损 3.15亿元至3.75亿元;扣除非经常性损益后的净亏损3.15亿元至3.75亿元。 ...